Relief Therapeutics Holding AG (RLFTF)

[Dougster]

BIG-News: OTCQB Certification; RLFTF: RELIEF THERAPEUTICS HLDG AG
Published: 2020-08-25 15:13:40 SEC.report OTC Filings : RLFTF OTCQB Certification
https://sec.report/otc/financial-report/256107
The U.S. Food and Drug Administration (FDA) has given Aviptadil the go-ahead for an accelerated approval process.
RLFTF QB Certification and fast-track profile Aviptadil testing bode well for stock this investment long-term.
RLF-100 is considered to be the first drug that blocks the propagation of coronavirus in human lung cells and monocytes. The hope is that the drug will prove beneficial by inhaling in a wider range of patients with corona-related breathing problems. Clinical trials will begin in September.
NEXT BIG-News: Testing Results of Relief Therapeutic's Aviptadil.
Aviptadil is considered an innovative drug for inhalation in moderate and severely ill corona patients. The remedy can prevent patients from having to be connected to ventilators - or from being no longer dependent on ventilators within a few days.
NEXT NEXT BIG-News: NOTATION; Talk of new similar virus being called Covid-20.